Gadolinium MRI Scan Lawsuit – In The News

Gadolinium, a contrast agent used in MRI and MRA scans has been linked to a painful condition affecting the skin and joints as well as impaired brain function.

FDA Requires New Warning On MRI 'Dyes' That Chuck Norris Says Poisoned His Wife


The Food and Drug Administration has announced that it will require new safety measures for certain contrast agents, or "dyes," used to enhance magnetic resonance imaging (MRI) scans, because small amounts of the compounds can be retained in the brain and other tissues.


FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings


The U.S. Food and Drug Administration (FDA) is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, and we have concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.


What is Gadolinium? Chuck Norris Claims It Poisoned His Wife


On Thursday, a law firm announced it was representing Chuck Norris in a suit against three different companies for $10 million in damages. Norris and his wife, Gena, claim that she has gadolinium deposition disease from medical scans taken five years ago. But what is gadolinium? And how controversial is its use?


Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms


Gadolinium chelates are widely used as contrast media for magnetic resonance imaging. The approved gadolinium-based contrast agents (GBCAs) have historically been considered safe and well tolerated when used at recommended dosing levels. However, for nearly a decade, an association between GBCA administration and the development of nephrogenic systemic fibrosis (NSF) has been recognized in patients with severe renal impairment.

READ MORE at the National Institute of Health

Gadolinium-based Contrast Agents (GBCAs): Drug Safety Communication - Retained in Body; New Class Warnings


The FDA issued a Drug Safety Communication today about gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) to alert health care professionals and patients about gadolinium retention in the body and to provide information on how to mitigate the risk. The FDA is requiring a new class warning for all GBCAs about gadolinium remaining in the body for months or years after receiving the drug.


New Study Reports Gadolinium Retention in 70 Cases with Normal Kidney Function

Today we have released our fourth research paper on gadolinium retention from Gadolinium-based Contrast Agents (GBCAs) administered for contrast-enhanced MRIs. The paper is titled “Gadolinium Retention from Contrast MRIs in 70 Cases with Normal Renal Function – 24-hour Urine Test Results”.


Gadolinium MRI Contrast Dye Lawsuit Survey
Please fill out the survey to see if you could qualify for a claim or call 877-539-1539 to speak with a representative.

Did you have any known kidney impairment BEFORE having an MRI or MRA and receiving Gadolinium?

Were you diagnosed with any of the following BEFORE having an MRI or MRA and receiving Gadolinium?

What State do you live in?

Have you had any of the following symptoms?

Are you currently represented by an attorney concerning Gadolinium?